Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for HALO
+0.92 (6.19%)
May 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.12 - 16.16
52 week 6.95 - 17.27
Open 15.12
Vol / Avg. 1.24M/1.45M
Mkt cap 2.01B
P/E     -
Div/yield     -
EPS -0.56
Shares 126.70M
Beta 1.13
Inst. own 68%
May 11, 2015
Q1 2015 Halozyme Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 6, 2015
Halozyme Therapeutics Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Mar 10, 2015
Halozyme Therapeutics Inc at Barclays Healthcare Conference
Mar 2, 2015
Q4 2014 Halozyme Therapeutics Inc Earnings Call
Mar 2, 2015
Q4 2014 Halozyme Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -17.36% -90.76%
Operating margin -12.68% -83.68%
EBITD margin - -81.34%
Return on average assets -12.80% -51.07%
Return on average equity -52.04% -640.16%
Employees 153 -
CDP Score - -


11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Halozyme Therapeutics Inc. is a biopharmaceutical company. The Company�s research focuses on human enzymes that alter the extracellular matrix. The Company�s proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter) and Intrexon Corporation (Intrexon), with approximately two approved products for marketing in Europe. The Company�s products include Hylenex Recombinant, Ultrafast Insulin Program, PEGPH20 and HTI-501.

Officers and directors

Kathryn E. Falberg Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
David A. Ramsay CPA Chief Financial Officer, Vice President
Age: 50
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 55
Bio & Compensation  - Reuters
Athena Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 42
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Bio & Compensation  - Reuters
Kenneth J. Kelley Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Randal J. Kirk Independent Director
Age: 61
Bio & Compensation  - Reuters
Connie L. Matsui Independent Director
Age: 61
Bio & Compensation  - Reuters
John S. Patton Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters